Medtronic and Edwards Duel in TAVR Space

A pair of studies support the long-term use of Medtronic’s CoreValve transcatheter aortic valve replacement (TAVR) system. The Dublin-based company unveiled results from both the Nordic Aortic Valve Intervention Trial (NOTION) and the CoreValve U.S. Pivotal Extreme Risk Study at the American College of Cardiology 67th Annual Scientific Session (ACC) this past weekend. NOTION is a physician-initiated trial that studied an all-comers population of 280 patients at least 70 years old. Patients in the trial were randomized to either Surgical Aortic Valve Replacement (SAVR) or TAVR procedures. Join us at the BIOMEDevice Boston Expo,  April 18–19, 2018. Use promo code "MDDI" for 20% off conference registration and free expo access.   Results at five-year follow-up from NOTION showed similar rates of all-cause mortality (27.7% for both TAVR and SAVR). The study also showed superior hemodynamic performance for TAVR, with a mean aortic valve gradient of 8.22 mmHg compared to surgery (13.71 mmHg.) “These five-year outcomes of the NOTION data add to the mounting body of longer-term evidence supporting the effectiveness of TAVR,” said Gustav Thyregod, M.D., Ph.D., cardiac surgeon in the department of cardiac surgery at The Heart Center, Rigshospitalet, in Copenhagen, Denmark, and presenter of the NOTION data at the meeting. "We're pleased to see the strong hemodynamic performance maintained over time without any indication of valve deterioration." The final five-year results ...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Cardiovascular Source Type: news